| 2.25 -0.03 (-1.32%) | 02-20 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |   |
|||
| Targets | 6-month : | 2.93 | 1-year : | 3.25 |
| Resists | First : | 2.51 | Second : | 2.78 |
| Pivot price | 2.2 |
|||
| Supports | First : | 2.05 | Second : | 1.71 |
| MAs | MA(5) : | 2.24 |
MA(20) : | 2.27 |
| MA(100) : | 2.88 |
MA(250) : | 3.05 |
|
| MACD | MACD : | -0.1 |
Signal : | -0.1 |
| %K %D | K(14,3) : | 48.5 |
D(3) : | 39.6 |
| RSI | RSI(14): 48.9 |
|||
| 52-week | High : | 13.93 | Low : | 1.89 |
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and NEUTRAL in mid-long term.[ XBIO ] has closed below upper band by 35.9%. Bollinger Bands are 82.5% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 63 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 2.25 - 2.27 | 2.27 - 2.28 |
| Low: | 2.17 - 2.19 | 2.19 - 2.2 |
| Close: | 2.23 - 2.25 | 2.25 - 2.27 |
Xenetic Biosciences, Inc., a biopharmaceutical company, focuses on advancing XCART, a personalized chimeric antigen receptor T cell (CAR T) platform technology engineered to target patient-specific tumor neoantigens. The company engages in the discovery, research, and development of biologic drugs and oncology therapeutics. It advances cell-based therapeutics targeting the B-cell receptor on the surface of an individual patient's malignant tumor cells for the treatment of B-cell lymphomas. It is also leveraging PolyXen, its proprietary drug delivery platform, by partnering with biotechnology and pharmaceutical companies. It has collaboration agreements with Takeda Pharmaceutical Co. Ltd., Serum Institute of India Limited, PJSC Pharmsynthez, and SynBio LLC. Xenetic Biosciences, Inc. is headquartered in Framingham, Massachusetts.
Sun, 15 Feb 2026
Xenetic Biosciences, Inc. Announces Adjournment of 2025 Annual Meeting - Courier & Press
Thu, 12 Feb 2026
Xenetic Biosciences appoints James Parslow as interim CEO - Intellectia AI
Fri, 10 Oct 2025
Xenetic Biosciences, Inc. Announces Pricing of $4.5 Million Underwritten Offering of Common Stock - ACCESS Newswire
Fri, 10 Oct 2025
Xenetic Biosciences prices $4.5 million common stock offering - Investing.com
Fri, 10 Oct 2025
$4.5M offering: Xenetic Biosciences prices 735,000 shares to fund working capital - Stock Titan
Wed, 08 Oct 2025
Xenetic Biosciences (XBIO) Stock Skyrockets – Is the Biotech’s 2025 Rally for Real? - TechStock²
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 2 (M) |
| Shares Float | 2 (M) |
| Held by Insiders | 10.2 (%) |
| Held by Institutions | 2.8 (%) |
| Shares Short | 5 (K) |
| Shares Short P.Month | 7 (K) |
| EPS | -1.96 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 2.55 |
| Profit Margin | -110.5 % |
| Operating Margin | -53.1 % |
| Return on Assets (ttm) | -31.6 % |
| Return on Equity (ttm) | -57.5 % |
| Qtrly Rev. Growth | 67.1 % |
| Gross Profit (p.s.) | 1.24 |
| Sales Per Share | 1.24 |
| EBITDA (p.s.) | 0 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -3 (M) |
| Levered Free Cash Flow | -3 (M) |
| PE Ratio | -1.16 |
| PEG Ratio | 0 |
| Price to Book value | 0.87 |
| Price to Sales | 1.8 |
| Price to Cash Flow | -1.9 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|